Table 3.

Subgroup analysis.

	mRS 0–2 (vs. 3-6) at 3 months		In-Hospital Mortality		All-Cause Mortality (3 months)		sICH
	mRS 0–2, n (%)	OR (95% CI); p*	mRS 6, n (%)	OR (95% CI); p	mRS 6, n (%)	OR (95% CI); p	sICH yes, n (%)	OR (95% CI); p
A: Etiology (Dissection, LAD, COMP)
Dissection	14 (53.8)	1.57 (0.69–3.59); 0.299	2 (7.7)	0.43 (0.10–1.92); 0.384	4 (15.4)	0.64 (0.21–1.97); 0.610	0 (n.a.)	n.a.; 1.000
LAD	71 (47.7)	1.63 (0.90–2.97); 0.138	19 (12.8)	0.55 (0.26–1.19); 0.152	26 (17.4)	0.50 (0.25–0.98); 0.048	6 (4.1)	2.79 (0.33–23.87); 0.439
LAD/CE	10 (24.4)	0.34 (0.16–0.75); 0.005	12 (29.3)	3.03 (1.32–6.95); 0.014	16 (39.0)	3.09 (1.45–6.61); 0.005	1 (2.4)	0.70 (0.08–6.01); 1.000
	mRS 0–2 (vs. 3–6) at 3 months		In-Hospital Mortality		All-Cause Mortality (3 months)		sICH
	mRS 0–2, n (%)	OR (95% CI); p	mRS 6, n (%)	OR (95% CI); p	mRS 6, n (%)	OR (95% CI); p	sICH yes, n (%)	OR (95% CI); p
B: Loading (ticagrelor/aspirin vs. clopidogrel/aspirin)
Clopidogrel	37 (44.6)	1.04 (0.51–2.09); 0.920	9 (10.8)	0.46 (0.17–1.25); 0.129	14 (16.9)	0.75 (0.27–2.13); 0.594	0 (n.a.)	n.a.; 0.048
Ticagrelor	62 (45.3)		24 (17.5)		32 (23.4)		7 (5.1)

LAD, large artery disease; LAD/CE, competing etiologies (LAD and cardiac embolism); mRS, modified Rankin Scale; OR, Odds ratio; CI, confidence interval; sICH, symptomatic intracranial hemorrhage; n.a., not applicable.

^*p-value for group comparison; outcome in one subgroup (e.g., dissection) vs. the remaining subgroups (LAD and LAD/CE).